Moonshot Is The Spanner In The Covid-19 Works The Country Needs
The title of this post, is the same as that of this article on The Times.
This is the sub-title of the article.
Antivirals like molnupiravir are the third line in our long-term fight against coronavirus.
The article describes how scientists in Oxfordshire looked for an antiviral that could be Covid-19’s nemesis, which Tom Whipple called molecular kryptonite.
The American pharmaceutical[ molnupiravir has been the first antiviral to be licenced for Covid-19, but it is pricey.
But helped by the Diamond Light Source, it appears that, progress has been made in Oxfordshire.
Tom Whipple says this.
After 18 months of study they last week gained funding from the Wellcome Trust to narrow the options to one, in a project called Covid Moonshot.
And this.
The goal of Moonshot is a generic drug that is cheap, plentiful and, a stipulation of the project, off-patent from the beginning.
Has the Diamond Light Source has struck again?
- The Diamond Light Source And COVID-19
- The Diamond Light Source And Ebola
- The Diamond Light Source And Malaria
The Diamond Light Source might have cost £ 400 million and needs a budget of £ 40 million a year to run, but it is certainly starting to pay back the investment.
The Anonymous Widower 